http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111701011-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2020-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111701011-B |
| titleOfInvention | Host defense peptide composition and its application in the preparation of antibacterial drugs |
| abstract | The invention belongs to the technical field of medicine and relates to the application of a host defense peptide composition in the preparation of antibacterial drugs, in particular to the application of the host defense peptide Caerin 1.1 and caerin 1.9 peptide compositions in the preparation of antibacterial drugs. The present invention provides compositions of caerin 1.1 peptides and caerin 1.9 peptides. Wherein, the weight ratio of caerin1.1 peptide to caerin 1.9 peptide is: 1:1-3. The antibacterial drug is used against bacteria of the skin and mucous membranes. The bacteria include but are not limited to Staphylococcus aureus (S.aureus), Pseudomonas aeruginosa (P.aeruginosa), Methicillin-resistant Staphylococcus aureus (MRSA, GDM1.1263) Acinetobacter baumannii ( Acinetobacter Baumannii, GDM1.609) or Neisseria gonorrhoeae and the like. The combined use of the caerin 1.1 peptide or the caerin 1.9 peptide of the present invention can exert a synergistic effect and have the best antibacterial effect. Can be used as a first-line mucocutaneous antibacterial drug. For the treatment of bacterial infections of the skin and mucous membranes. |
| priorityDate | 2020-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.